Re-evaluating Severe Cutaneous Adverse Events to Enfortumab Vedotin: TEC rather than TEN
Journal of the American Academy of Dermatology · 2026-10
DOI: 10.1016/j.jaad.2026.09.128 ↗Kurz gefasst
Leserbrief in der Zeitschrift Journal of the American Academy of Dermatology, 2026-10. Verfasst von Rentao Yu und 5 weiteren Autor:innen. Beteiligte Einrichtung: The Department of Dermatology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. Gefördert von: Bethune Charitable Foundation.
Themen: Patientensicherheit
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- The Department of Dermatology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
- The Department of Dermatology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China; The Department of Dermatology, The ChenJiaqiao Hospital of Shapingba Distict of Chongqing, Chongqing, China.
- The Department of Dermatology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China; The Department of Dermatology, Chongqing Nanchuan District People's Hospital, Chongqing, China.
- The Department of Dermatology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. Electronic address: chenaijun@hospital.cqmu.edu.cn.
Förderung
- Bethune Charitable Foundation
Zitieren
APA
Yu, R., Gu, L., Wu, Q., Pan, Y., Li, F., & Chen, A. (2026). Re-evaluating Severe Cutaneous Adverse Events to Enfortumab Vedotin: TEC rather than TEN. Journal of the American Academy of Dermatology. https://doi.org/10.1016/j.jaad.2026.09.128
Vancouver
Yu R, Gu L, Wu Q, Pan Y, Li F, Chen A. Re-evaluating Severe Cutaneous Adverse Events to Enfortumab Vedotin: TEC rather than TEN. Journal of the American Academy of Dermatology. 2026. doi:10.1016/j.jaad.2026.09.128
BibTeX
@article{Yu2026,
author = {Yu, Rentao and Gu, Ling and Wu, Qian and Pan, Yun and Li, Fengzeng and Chen, Aijun},
title = {Re-evaluating Severe Cutaneous Adverse Events to Enfortumab Vedotin: TEC rather than TEN},
journal = {Journal of the American Academy of Dermatology},
year = {2026},
doi = {10.1016/j.jaad.2026.09.128}
}
EUVIMED